APA (7th ed.) Citation

Lu, X., Dai, T., Chen, X., Wu, B., Chen, H., Wu, J., . . . Ye, D. A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer. BMC.

Chicago Style (17th ed.) Citation

Lu, Xiaolin, et al. A Randomized, Open-label, Multi-center, Active-controlled Phase II Study Comparing Abiraterone Acetate Tablets (II), an Improved Formulation, Versus Originator Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer. BMC.

MLA (9th ed.) Citation

Lu, Xiaolin, et al. A Randomized, Open-label, Multi-center, Active-controlled Phase II Study Comparing Abiraterone Acetate Tablets (II), an Improved Formulation, Versus Originator Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer. BMC.